See today's BioWorld
To read the full story, subscribe or sign in.

Portola turns to FDA for antidote to Andexxa CRL

Aug. 19, 2016
By Michael Fitzhugh
An FDA complete response letter (CRL) for Portola Pharmaceuticals Inc.'s factor Xa inhibitor antidote, Andexxa (andexanet alfa), left the company "significantly surprised," said CEO Bill Lis.
BioWorld